Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance

MARAVAI LIFESCIENCES HOLDINGS, INC.

2026-Q1 EPS reported -$0.02 revenue$65,837,000

Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.
Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.
TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.
Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.
Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.